Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

Journal of Viral Hepatitis

Volumn 20, Issue 8, 2013, Pages 524-529

  Manns, M P ^a   Pockros, P J ^b   Norkrans, G ^c   Smith, C I ^d   Morgan, T R ^e   Haussinger D ^f   Shiffman, M L ^g   Hadziyannis, S J ^h   Schmidt, W N ⁱ   Jacobson, I M ^j   Barcena R ^k   Schiff, E R ^l   Shaikh, O S ^m   Bacon, B ⁿ   Marcellin, P ^o   Deng, W ^p   Esteban Mur, R ^q   Poynard, T ^r   Pedicone, L D ^p   Brass, C A ^p   Albrecht, J K ^p   Gordon, S C ^s   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SCRIPPS CLINIC   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g Bon Secours Health System   (United States)

^h HENRY DUNANT HOSPITAL   (Greece)

ⁱ UNIVERSITY OF IOWA   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁿ Saint Louis University   (United States)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p MERCK RESEARCH LABORATORIES   (United States)

^q HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^r SORBONNE UNIVERSITÉ   (France)

^s HENRY FORD HEALTH SYSTEM   (United States)

more..

Author keywords

clinical; cure; eradication; follow up; longitudinal

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD;

CLINICAL; CURE; ERADICATION; FOLLOW-UP; LONGITUDINAL;

DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84879795584     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12074     Document Type: Article

References (11)

1. Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.
2. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-787.
3. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516.
4. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Davis GL, Esteban-Mur R, Rustgi V, et al,. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
6. McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
7. Poynard T, Marcellin P, Lee SS, et al,. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
8. Lindsay KL, Trepo C, Heintges T, et al,. A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
9. Desmond CP, Roberts SK, Dudley F, et al,. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13: 311-315.
10. Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-508.
11. Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon α-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.